Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01372163 · ClinicalTrials.gov registry record · Phase 1
A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients
A Phase 1 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT01372163 is a Phase 1 study that was terminated before completion, run by Pfizer. The registered enrollment target is 35 participants.
The verdict
NCT01372163, a Phase 1 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and tolerability of PF-05190457 after administration of multiple doses to healthy volunteers and Type 2 diabetic patients and to evaluate the plasma drug concentrations after multiple doses.
Interventions
- DRUG PF-05190457 or Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2011-07 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01372163
The ClinicalTrials.gov registry entry for NCT01372163 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PF-05190457 or Placebo is the first listed.
NCT01372163 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01372163 about?
NCT01372163 is a clinical study titled "A Study Of PF-05190457 In Healthy Volunteers And Type-2 Diabetic Patients". The purpose of the study is to evaluate the safety and tolerability of PF-05190457 after administration of multiple doses to healthy volunteers and Type 2 diabetic patients and to evaluate the plasma drug concentrations after multiple doses.
What is the current status of trial NCT01372163?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2011-07. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01372163?
The interventions under investigation include: PF-05190457 or Placebo (DRUG).
Who is sponsoring clinical trial NCT01372163?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.